SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

Home・Akcijų sąrašas・Bayer AG

Bayer AG

Atidarymo kaina

SektoriusFinansų sektorius

36.08 2.91

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

35.02

Max

35.93

Pagrindiniai rodikliai
By Trading Economics
Pajamos	6.5B 2.8B
Pardavimai	2B 13B
Pelnas, tenkantis vienai akcijai	2.812
Dividendų pajamingumas	0.3
Pelno marža	20.612
Darbuotojai	87,757
EBITDA	2.3B 4.4B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+42.8% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.30% 4.65%
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.9B 35B
Ankstesnė atidarymo kaina	33.17
Ankstesnė uždarymo kaina	36.08

Naujienos nuotaikos

By Acuity

29%

71%

57 / 439 reitingas Finance

Bayer AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-02 11:21; UTC

Pagrindinės rinkos jėgos

Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement

2026-05-12 11:24; UTC

Uždarbis

Pagrindinės rinkos jėgos

Bayer Shares Climb After Earnings Beat Expectations

2026-05-12 06:10; UTC

Uždarbis

Bayer Net Profit Surges Driven by Growth in Agricultural Division

2026-05-06 10:51; UTC

Įsigijimai, susijungimai, perėmimai

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

2026-05-06 07:01; UTC

Įsigijimai, susijungimai, perėmimai

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

2026-06-02 11:22; UTC

Rinkos pokalbiai

Bayer Hit by New Roundup Legal Jitters -- Market Talk

2026-05-29 08:15; UTC

Rinkos pokalbiai

Uždarbis

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

2026-05-29 07:42; UTC

Rinkos pokalbiai

Bayer Can Still Take Hit if Litigation Strategy Fails -- Market Talk

2026-05-12 12:05; UTC

Karštos akcijos

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

2026-05-12 10:51; UTC

Karštos akcijos

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

2026-05-12 09:08; UTC

Karštos akcijos

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

2026-05-12 05:38; UTC

Uždarbis

Bayer Backs 2026 Outlook Adjusted for Currency

2026-05-12 05:36; UTC

Uždarbis

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

2026-05-12 05:36; UTC

Uždarbis

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

2026-05-12 05:36; UTC

Uždarbis

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

2026-05-12 05:35; UTC

Uždarbis

Bayer 1Q Adj EPS EUR2.71

2026-05-12 05:34; UTC

Uždarbis

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

2026-05-12 05:34; UTC

Uždarbis

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

2026-05-12 05:34; UTC

Uždarbis

Analysts Saw Bayer 1Q Sales at EUR13.42B

2026-05-12 05:34; UTC

Uždarbis

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

2026-05-12 05:33; UTC

Uždarbis

Bayer 1Q EBIT EUR3.53B

2026-05-12 05:32; UTC

Uždarbis

Bayer 1Q Ebitda Before Special Items EUR4.45B

2026-05-12 05:32; UTC

Uždarbis

Bayer 1Q Net Pft EUR2.76B

2026-05-12 05:31; UTC

Uždarbis

Bayer 1Q Sales EUR13.405B

2026-05-12 05:31; UTC

Uždarbis

Bayer Backs 2026 View

2026-05-06 06:34; UTC

Įsigijimai, susijungimai, perėmimai

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

2026-05-06 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

2026-05-06 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

2026-05-06 06:32; UTC

Įsigijimai, susijungimai, perėmimai

Bayer to Pay $300M Upfront

2026-05-06 06:32; UTC

Įsigijimai, susijungimai, perėmimai

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

Akcijų palyginimas

Kainos pokytis

Bayer AG Prognozė

Kainos tikslas

By TipRanks

42.8% į viršų

12 mėnesių prognozė

Vidutinis 49.55 EUR 42.8%

Aukščiausias 56 EUR

Žemiausias 40 EUR

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bayer AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Bayer AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

57 / 439 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.